# 2026-08378: FDA Renews Pharmacy Compounding Advisory Committee for Two Years

2026-08378, Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-30, effective 2026-04-25 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08378
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08378
- Title: Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 23275
- Published: 2026-04-30
- Effective: 2026-04-25
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Renews Pharmacy Compounding Advisory Committee for Two Years

## Summary

The FDA is renewing the Pharmacy Compounding Advisory Committee for two more years, keeping it active until April 25, 2028. This committee helps the FDA make smart decisions about how medicines are safely mixed and prepared by pharmacists. If you’re involved in pharmacy or drug safety, this renewal means expert advice will keep guiding important rules without extra costs or delays.

## Abstract

The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Pharmacy Compounding Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pharmacy Compounding Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the April 25, 2028, expiration date.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08378 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/30/2026-08378/advisory-committee-pharmacy-compounding-advisory-committee-renewal)
- [2026-08378 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-30/pdf/2026-08378.pdf)

## Related
- [Previous: 2026-08377, Proposed Extension of Information Collection; Consumer Price Index Commodities…](https://policyrisk.com/federal-register/2026-08377)
- [Next: 2026-08379, Environmental Protection Agency Draft Fiscal Year 2027 Evidence Plan](https://policyrisk.com/federal-register/2026-08379)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08378 (as of 2026-06-08).
